LDE225 0.75%
CLDE225B2204
Phase 2 small_molecule terminated
Quick answer
LDE225 0.75% for Sporadic Superficial and Nodular Skin Basal Cell Carcinomas is a Phase 2 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Pharmaceuticals
- Indication
- Sporadic Superficial and Nodular Skin Basal Cell Carcinomas
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated